Compared to Estimates, Nutrien (NTR) Q4 Earnings: A Look at Key Metrics

Zacks
20 Feb

Nutrien (NTR) reported $5.08 billion in revenue for the quarter ended December 2024, representing a year-over-year decline of 10.3%. EPS of $0.31 for the same period compares to $0.37 a year ago.

The reported revenue represents a surprise of -1.42% over the Zacks Consensus Estimate of $5.15 billion. With the consensus EPS estimate being $0.33, the EPS surprise was -6.06%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Nutrien performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Tonnes Sold - Potash - Total: 2,758 KTon compared to the 2,719.55 KTon average estimate based on five analysts.
  • Tonnes Sold - Nitrogen: 2,914 KTon compared to the 2,892.23 KTon average estimate based on five analysts.
  • Average Selling Price per Tonne - Phosphate - Industrial and feed: 812 $/Ton versus 834.51 $/Ton estimated by five analysts on average.
  • Average Selling Price per Tonne - Phosphate - Total: 671 $/Ton compared to the 579.94 $/Ton average estimate based on five analysts.
  • Sales- Retail Total: $3.18 billion versus $3.29 billion estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -9.2% change.
  • Sales- Potash: $587 million versus $639.23 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -32% change.
  • Sales- Phosphate: $471 million versus $474.84 million estimated by six analysts on average. Compared to the year-ago quarter, this number represents a -23.4% change.
  • Sales- Nitrogen: $1.18 billion compared to the $1.10 billion average estimate based on six analysts. The reported number represents a change of +5.2% year over year.
  • Net Sales- Eliminations: -$356 million versus -$401.44 million estimated by five analysts on average. Compared to the year-ago quarter, this number represents a -1.9% change.
  • Sales- Retail (Nutrient Ag Solutions)- Crop protection products: $948 million versus $946.09 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -1.3% change.
  • Sales- Retail (Nutrient Ag Solutions)- Crop nutrients: $1.53 billion compared to the $1.56 billion average estimate based on four analysts. The reported number represents a change of -15.5% year over year.
  • Net Sales- Phosphate: $414 million versus the four-analyst average estimate of $426.49 million. The reported number represents a year-over-year change of -22.3%.
View all Key Company Metrics for Nutrien here>>>

Shares of Nutrien have returned +0.7% over the past month versus the Zacks S&P 500 composite's +2.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Nutrien Ltd. (NTR) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10